On November 9, 2020 TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, reported that management will present virtually at the following upcoming medical meeting and healthcare conferences (Press release, TScan Therapeutics, NOV 9, 2020, View Source [SID1234570520]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting (SITC) (Free SITC Whitepaper)

Gavin MacBeath, Ph.D., Chief Scientific Officer, will present an e- poster entitled "Discovery of TSC-100: A Natural HA-1-specific TCR to Treat Leukemia Following Hematopoietic Stem Cell Transplant Therapy". The poster will be available for viewing in the Virtual Poster Hall on Monday, November 9, 2020, at 8:00 a.m. Eastern Time.
Jefferies London Global Healthcare Conference

David Southwell, Chief Executive Officer, will present a company overview on Thursday, November 19, 2020, at 10:50 a.m. Eastern Time.
3rd Annual Evercore ISI HealthCONx Conference

Mr. Southwell will participate in a panel discussion entitled "Finders Keepers: Identifying New Cancer Targets with Atreca, TScan Therapeutics" on Wednesday, December 2, 2020, at 10:30 a.m. Eastern Time.